The Latest Cardiac and Vascular News
CHENGDU, China, July 14, 2026 /PRNewswire/ — Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”, SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. (“BioAge”, NASDAQ: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for…
CHENGDU, China–(BUSINESS WIRE)–Lipigon Pharmaceuticals AB (”Lipigon”), developer of therapeutics for lipid-related diseases, today announced that the company has expanded its agreement with the Shanghai STAR listed company HitGen Inc. (”HitGen”) to include a second novel target. With joint efforts, the aim is to develop a treatment for cardiometabolic disease. Lipigon […]
